Abstract
Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15–20. https://doi.org/10.1038/sj.bmt.1702731.
Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517–526. https://doi.org/10.1016/s1470-2045(14)70202-5.
Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014;49:1266–8. https://doi.org/10.1038/bmt.2014.143.
Phillips EH, Hodson A, Hermine O, Bazarbachi A, Cwynarski K. Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant? Bone Marrow Transplant. 2016;51:1549–55. https://doi.org/10.1038/bmt.2016.154.
Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–76. https://doi.org/10.1182/blood-2009-10-247510.
Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426–33. https://doi.org/10.1200/jco.2016.67.8250.
Inoue Y, Fuji S, Tanosaki R, Inamoto Y, Tanaka T, Ito A. et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant. 2018;53:1105–15. https://doi.org/10.1200/jco.2016.67.8250.
Yoshimitsu M, Tanosaki R, Kato K, Ishida T, Choi I, Takatsuka Y et al. Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; 24(4): 832-839. e-pub ahead of print 2017/11/21; https://doi.org/10.1016/j.bbmt.2017.11.005.
Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016;51:205–11. https://doi.org/10.1038/bmt.2015.265.
Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y et al. Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2014; 20(12): 1968-1974. e-pub ahead of print 2014/08/31; https://doi.org/10.1016/j.bbmt.2014.08.012.
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50. https://doi.org/10.1016/j.bbmt.2008.03.005.
O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.
Kasamon YL, Bolanos-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33:3152–61. https://doi.org/10.1200/jco.2014.60.4777.
Ghosh N, Ye X, Tsai HL, Bolanos-Meade J, Fuchs EJ, Luznik L, et al. Allogeneic blood or marrow transplantation with post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis in multiple myeloma. Biol Blood Marrow Transplant. 2017;23:1903–9. https://doi.org/10.1016/j.bbmt.2017.07.003
Obama K, Utsunomiya A, Takatsuka Y, Takemoto Y. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant. 2004;34:897–9. https://doi.org/10.1038/sj.bmt.1704692.
Fujiwara H, Ozaki A, Yoshimitsu M, Hamada H, Masamoto I, Matsushita K, et al. Allogeneic stem cell transplantation for refractory adult T-cell leukemia using a non-T-cell-depleted HLA-incompatible family donor graft, with reference to the grown-up child donor to parent recipient setting: report of a pilot study. Int J Hematol. 2008;87:319–26. https://doi.org/10.1007/s12185-008-0042-2.
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9. https://doi.org/10.1016/j.bbmt.2008.12.497.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004.
Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone marrow transplantation 2013; 48 Suppl 1: S1-37. e-pub ahead of print 2013/03/15; https://doi.org/10.1038/bmt.2012.282.
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone marrow transplantation 2013; 48(3): 452-458. e-pub ahead of print 2012/12/05; https://doi.org/10.1038/bmt.2012.244.
Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–41. https://doi.org/10.1182/blood-2012-03-414490.
Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et al. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant. 2015;21:1495–505. https://doi.org/10.1016/j.bbmt.2015.04.012.
Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K, et al. Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis. Bone Marrow Transplant. 2018. https://doi.org/10.1038/s41409-017-0082-4.
Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y et al. Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-1: a nationwide survey. Cancer Sci. 2017;108:2478-86. https://doi.org/10.1111/cas.13398
Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymph. 2017;58:1840–8. https://doi.org/10.1080/10428194.2016.1266624.
Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–73. https://doi.org/10.1016/s1470-2045(15)00462-3.
Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005; 105(10): 4143-4145. e-pub ahead of print 2005/01/25; https://doi.org/10.1182/blood-2004-11-4193.
Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1279–87. https://doi.org/10.1016/j.bbmt.2008.08.014.
Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017;35:3002–9. https://doi.org/10.1200/jco.2017.72.8428.
Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, et al. Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2017;23:318–24. https://doi.org/10.1016/j.bbmt.2016.11.008.
Acknowledgements
We thank all the physicians and data managers at the participating institutions, who contributed valuable data on transplantation for ATL to the JSHCT. We also thank all members of the data management committees of the JSHCT.
ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
Koji Kato, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan. Takashi Ishida, Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan. Atae Utsunomiya, Department of Hematology, Imamura General Hospital, Kagoshima, Japan. Junji Suzumiya, Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, Izumo, Japan. Yoshifusa Takatsuka, Department of Hematology, Izuro Imamura Hospital, Kagoshima, Japan. Tomomi Tobai, Department of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan. Koichi Nakase, Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan. Yuichiro Nawa, Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan. Masakatsu Hishizawa, Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Takuya Fukushima, Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan. Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Nishihara, Japan. Masato Masuda, Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan. Cancer Centre, University of the Ryukyus, Nishihara, Japan. Atsushi Wake, Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan. Choi Ilseung, Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan. Yoshitaka Asakura, Department of Hematology, Okinawa Red Cross Hospital, Naha, Japan. Nobuaki Nakano, Department of Hematology, Imamura General Hospital, Kagoshima, Japan. Hiroshi Fujiwara, Department of Immuno-gene therapy, Center for Comprehensive Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan. Shinichiro Machida, Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan. Yasushi Sawayama, Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan. Kohei Tada, Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. Yoshitaka Inoue, Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan. Kazunori Imada, Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan. Isao Yoshida, Department of Hematologic Oncology, Shikoku Cancer Center, Matsuyama, Japan. Makoto Yoshimitsu, Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan. Shigeo Fuji, Department of Hematology, Osaka International Cancer Center, Osaka, Japan. Takahiro Fukuda, Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. Takero Shindo, Department of Hematology/Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Masahito Tokunaga, Department of Hematology, Imamura General Hospital, Kagoshima, Japan. Hiroyuki Muranushi, Department of Hematology/Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Satoko Morishima, Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan. Shohei Tomori, Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan. Tomoki Iemura, Department of Hematology/Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Author contributions
MY, AU, SF, HF, TF, and KK designed the research, organized the project, and wrote the paper. MY performed the statistical analyses. H Ogawa, YT, KI, AY, H Okumura, KI, AN, TE, AY, KM, J Tsukada, J Tanaka, and YA gathered the data. All authors contributed to the final version of the manuscript and have approved it for submission for publication.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Yoshimitsu, M., Utsunomiya, A., Fuji, S. et al. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma. Bone Marrow Transplant 54, 1266–1274 (2019). https://doi.org/10.1038/s41409-018-0400-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0400-5
This article is cited by
-
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma
Bone Marrow Transplantation (2024)
-
Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma
Bone Marrow Transplantation (2023)
-
Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma
Bone Marrow Transplantation (2021)
-
GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
Bone Marrow Transplantation (2021)
-
Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission
Annals of Hematology (2020)